Pfizer will list its COVID-19 treatment Paxlovid at a price of $1,390 per five-day course when it soon hits the commercial market, the drugmaker confirmed to Axios.
Why it matters: Paxlovid’s new listed price, first reported by the Wall Street Journal, will be more than twice the $529 paid by the federal government, which until now has maintained the entire U.S. supply of the key antiviral medication.
Only 2.6% of the sample were given paxlovid, and they didn’t control for vaccination status.
Also, it only covered 1 month nearly 2 years ago in a single country, and the virus has mutated several times since then.
Paxlovid is a 3CL protease inhibitor. It modifies the primary enzyme that is common across all cornavirus.
The best part about having a background in statistics is watching people who don’t understand statistics try to explain why the math that doesn’t support their point actually does, somehow.
Statistics don’t matter if your methodology is flawed.